Table 2.

Differential expression of markers of immune functional orientation in IBE-FID and IBD-FID tumors

IBE-FID vs. IBD-FID
Marker name/functional typeMean log differenceaPb
ICR: Th1 polarization
IFNG | 210354_at0.527.6E−07
IRF1 | 202531_at0.247.6E−05
STAT1 | 209969_s_at0.564.3E−07
IL12B | 207901_at0.038.5E−01
TBX21 | 220684_at0.139.6E−02
IL12A | 207160_at0.095.2E−01
ICR: Cytotoxic mechanisms
GZMB | 210164_at0.961.3E−12
GNLY | 205495_s_at0.653.4E−06
PRF1 | 214617_at0.364.8E−04
GZMH | 210321_at0.524.2E−03
GZMA | 205488_at0.228.9E−02
ICR: Tissue rejection chemokines
CXCL10 | 204533_at0.907.6E−11
CXCL9 | 203915_at0.832.7E−08
CX3CL1 | 203687_at0.463.5E−03
CCL5 | 1405_i_at0.436.9E−04
CCL2 | 216598_s_at0.209.5E−02
ICR: Adhesion molecules
ICAM1 | 202637_s_at, 215485_s_at0.181.2E−02
VCAM1 | 203868_s_at0.141.4E−01
MADCAM1 | 208037_s_at−0.122.4E−01
CTL activation and regulatory markers
CD8A | 205758_at0.152.8E−01
CD8B | 207979_s_at, 215332_s_at0.114.1E−01
CD28 | 206545_at0.029.0E−01
CD86 | 205686_s_at0.258.3E−04
CD80 | 207176_s_at0.152.1E−02
CTLA4 | 221331_x_at0.291.7E−02
PDCD1 | 207634_at0.038.1E−01
FOXP3 | 221333_at−0.152.5E−01
NK cell activation and regulatory markers
KLRK1 (NKG2D) | 205821_at0.029.0E−01
MICA | 205904_at−0.085.0E−01
MICB | 206247_at−0.085.2E−01
ULBP1 | 221323_at0.057.9E−01
ULBP2 | 221291_at−0.029.0E−01
Protumorigenic cytokines
TGFB1 |203085_s_at−0.251.4E−03
IL8 | 202859_x_at0.361.0E−01
IL10 | 207433_at−0.134.2E−01
TGFB2 | 220407_s_at0.124.1E−01
  • aPositive values reflect log fold increase in IBE–FID relative to IBD–FID.

  • bAdjusted for false discovery.